Novo Nordisk A/S $NVO is Folketrygdfondet's Largest Position

Key Points

• Folketrygdfondet remains a major Novo Nordisk shareholder, even after trimming its stake by 0.5% in the fourth quarter. Novo Nordisk is still its largest position, making up about 33.3% of the fund’s portfolio.
• Analyst sentiment is mixed, with several recent downgrades offset by a few upgrades. Overall, the stock currently carries a consensus rating of “Hold” and an average price target of $65.56.
• Novo Nordisk’s latest results showed solid profitability, including $1.03 in quarterly EPS and $10.85 billion in revenue. The stock also rose 2.7% in recent trading, and investors are watching optimism around the Wegovy pill approval and the company’s obesity pipeline.

Folketrygdfondet cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 0.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,164,137 shares of the company's stock after selling 47,776 shares during the period. Novo Nordisk A/S comprises about 33.3% of Folketrygdfondet's investment portfolio, making the stock its biggest holding. Folketrygdfondet owned approximately 0.23% of Novo Nordisk A/S worth $517,151,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Godfrey Financial Associates Inc. purchased a new position in shares of Novo Nordisk A/S during the 4th quarter valued at approximately $25,000. WealthCollab LLC increased its stake in shares of Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company's stock worth $27,000 after buying an additional 260 shares during the last quarter. American National Bank & Trust acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at $28,000. Jackson Grant Investment Advisers Inc. acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at $29,000. Finally, Maseco LLP bought a new position in Novo Nordisk A/S during the 4th quarter valued at $29,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NVO has been the subject of several research analyst reports. Weiss Ratings downgraded shares of Novo Nordisk A/S from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Wednesday, April 22nd. Zacks Research raised shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 10th. TD Cowen downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $42.00 price target for the company. in a research note on Tuesday, March 10th. Jefferies Financial Group raised Novo Nordisk A/S from an "underperform" rating to a "hold" rating in a report on Thursday, February 12th. Finally, Wolfe Research started coverage on Novo Nordisk A/S in a research note on Thursday, March 26th. They set a "peer perform" rating on the stock. Four equities research analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $65.56.

Novo Nordisk A/S Stock Up 2.7%

NVO stock opened at $43.98 on Friday. The firm has a market cap of $196.37 billion, a price-to-earnings ratio of 10.32, a PEG ratio of 3.83 and a beta of 0.78. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $81.44. The firm has a fifty day moving average price of $42.13 and a two-hundred day moving average price of $46.01. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The company had revenue of $10.85 billion for the quarter. Research analysts predict that Novo Nordisk A/S will post 3.45 EPS for the current year.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: The U.K. Medicines and Healthcare products Regulatory Agency approved Novo Nordisk’s Wegovy pill, making it the first daily GLP-1 weight-loss tablet cleared in the country and opening another major market for the company’s obesity franchise. UK approves Novo weight-loss pill to edge open European market
• Positive Sentiment: Multiple reports highlighted that the approval could strengthen Novo Nordisk’s competitive position versus Eli Lilly by expanding access to an oral alternative to injectable obesity treatments. Novo Nordisk's Wegovy Weight Loss Pill Approved in the U.K.
• Positive Sentiment: Analyst-style and market commentary noted that Novo Nordisk’s obesity pipeline remains a key growth driver, with recent Phase 3 data for CagriSem adding to enthusiasm around its longer-term GLP-1 strategy. Novo Nordisk (NVO): Top 10 Large Cap Value Stocks to Buy Now
• Neutral Sentiment: Market wrap articles showed NVO outperforming the broader market in recent trading, reflecting renewed investor interest after the regulatory win. Novo Nordisk (NVO) Outpaces Stock Market Gains: What You Should Know
• Negative Sentiment: Novo Nordisk also disclosed a cybersecurity incident involving unauthorized access to internal IT systems and possible copying of non-public data, which could weigh on sentiment if the breach proves material. Novo Nordisk hit by cyber incident, probes data breach
• Negative Sentiment: A Reuters report said some U.S. employers may drop coverage of GLP-1 obesity drugs in 2027, a potential headwind for future demand growth across the category, including Wegovy. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.